Key Details
Annual ROE
-74.91%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 10, 2023Recent annual earnings:
Mar 14, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
May 23, 2023Analyst ratings
Recent major analysts updates
05 July '23 Canaccord Genuity
Buy03 July '23 Morgan Stanley
Equal-Weight30 June '23 Morgan Stanley
Equal-Weight30 June '23 BTIG
Neutral26 May '23 Morgan Stanley
Equal-Weight25 May '23 Morgan Stanley
Equal-Weight18 Jan '23 Canaccord Genuity
Buy23 Dec '21 Canaccord Genuity
Buy01 Dec '21 Barclays
Overweight30 Nov '21 Morgan Stanley
Equal-WeightScreeners with SGTX included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Sigilon Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly
SGTX
Zacks Investment Research30 June 2023
Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.
Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?
SGTX
InvestorPlace29 June 2023
Sigilon Therapeutics (NASDAQ: SGTX ) stock is rocketing on Thursday morning after Eli Lilly (NYSE: LLY ) agrees to acquire the company. The acquisition will see Eli Lilly pay $14.92 per share in cash and one tradeable contingent value right for each share of SGTX stock.
FAQ
- What is the primary business of Sigilon Therapeutics?
- What is the ticker symbol for Sigilon Therapeutics?
- Does Sigilon Therapeutics pay dividends?
- What sector is Sigilon Therapeutics in?
- What industry is Sigilon Therapeutics in?
- What country is Sigilon Therapeutics based in?
- When did Sigilon Therapeutics go public?
- Is Sigilon Therapeutics in the S&P 500?
- Is Sigilon Therapeutics in the NASDAQ 100?
- Is Sigilon Therapeutics in the Dow Jones?
- When was Sigilon Therapeutics's last earnings report?
- When does Sigilon Therapeutics report earnings?
- Should I buy Sigilon Therapeutics stock now?
What is the primary business of Sigilon Therapeutics?
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What is the ticker symbol for Sigilon Therapeutics?
The ticker symbol for Sigilon Therapeutics is NASDAQ:SGTX
Does Sigilon Therapeutics pay dividends?
No, Sigilon Therapeutics does not pay dividends
What sector is Sigilon Therapeutics in?
Sigilon Therapeutics is in the Healthcare sector
What industry is Sigilon Therapeutics in?
Sigilon Therapeutics is in the Biotechnology industry
What country is Sigilon Therapeutics based in?
Sigilon Therapeutics is headquartered in United States
When did Sigilon Therapeutics go public?
Sigilon Therapeutics's initial public offering (IPO) was on 04 December 2020
Is Sigilon Therapeutics in the S&P 500?
No, Sigilon Therapeutics is not included in the S&P 500 index
Is Sigilon Therapeutics in the NASDAQ 100?
No, Sigilon Therapeutics is not included in the NASDAQ 100 index
Is Sigilon Therapeutics in the Dow Jones?
No, Sigilon Therapeutics is not included in the Dow Jones index
When was Sigilon Therapeutics's last earnings report?
Sigilon Therapeutics's most recent earnings report was on 10 November 2023
When does Sigilon Therapeutics report earnings?
The date for Sigilon Therapeutics's next earnings report has not been announced yet
Should I buy Sigilon Therapeutics stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions